A national study for blood based response monitoring of newly diagnosed DLBCL patients

A national study for blood based response monitoring of newly diagnosed DLBCL patients - HOVON 902 DLBCL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52589

Enrollment

250

Registered

2020-01-14

Start date

2020-03-20

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive B-cell Lymphoma non-Hogkin Lymphoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *Patients diagnosed with newly diagnosed DLBCL (including HGBCL- NOS and HGBCL-DH) according to WHO classification 2016 * Ann Arbor stage II-IV * Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible) * Age >= 18 years

Exclusion criteria

Exclusion criteria: * Patients with limited stage II disease planned to receive 3 cycles of R-CHOP + radiotherapy, or 4 x R-CHOP+ 2R

Design outcomes

Primary

Measure	Time frame
The realisation of a reliable blood based assay that identifies primary refractory and early relapsing patients with DLBCL treated in first-line.	—

Secondary

Measure	Time frame
The realisation of a database that integrates the data of the blood based assay to the clinical data and to molecular pre-treatment tissue profiles	—

Countries

Netherlands

Outcome results